Back

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after three years of observation.

11 May 2026 (16:30 - 17:15)
Organised by: Logo
Congress Presentation Part of: Beyond glycaemia: pleiotropic mechanisms and emerging clinical effects of SGLT2 inhibitors in heart failure Antidiabetic Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)

5 More presentations in this session

Presentation thumbnail
Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure
Mr A. Hacil (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Sglt2 inhibitors and outcomes in patients with diabetes after durable lvad implantation: a multicenter real-world cohort study
Doctor W. Hsu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Impact of sodium-glucose cotransporter-2 inhibitors on clinical outcomes in patients with valvular heart diseases and type 2 diabetes
Assistant Professor D. Kim (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Uncoupling erythropoiesis from cardiorenal effects: SGLT2 inhibition in non-diabetic heart failure
Doctor D. Magureanu (Cluj Napoca, RO)
Abstract Slides Video
Presentation thumbnail
The effect of SGLT2 inhibitors in peripheral tissue oxygenation in patients with heart failure; A Near-infrared spectroscopy study
Doctor A. Ntalianis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Beyond glycaemia: pleiotropic mechanisms and emerging clinical effects of SGLT2 inhibitors in heart failure

The Event

Event poster

Heart Failure 2026

11 May 2026 16:30 CET
You may be interested in
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources